SOCS2 Can Enhance Interleukin-2 (IL-2) and IL-3 Signaling by Accelerating SOCS3 Degradation

Overview

Journal Mol Cell Biol

Specialty Cell Biology

Date 2005 Oct 4

PMID 16199887

Citations 64

Authors

Gillian M Tannahill

Joanne Elliott

Anna C Barry

Linda Hibbert

Nicolas A Cacalano

James A Johnston

Affiliations

Soon will be listed here.

Abstract

Cytokine responses can be regulated by a family of proteins termed suppressors of cytokine signaling (SOCS) which can inhibit the JAK/STAT pathway in a classical negative-feedback manner. While the SOCS are thought to target signaling intermediates for degradation, relatively little is known about how their turnover is regulated. Unlike other SOCS family members, we find that SOCS2 can enhance interleukin-2 (IL-2)- and IL-3-induced STAT phosphorylation following and potentiate proliferation in response to cytokine stimulation. As a clear mechanism for these effects, we demonstrate that expression of SOCS2 results in marked proteasome-dependent reduction of SOCS3 and SOCS1 protein expression. Furthermore, we provide evidence that this degradation is dependent on the presence of an intact SOCS box and that the loss of SOCS3 is enhanced by coexpression of elongin B/C. This suggests that SOCS2 can bind to SOCS3 and elongin B/C to form an E3 ligase complex resulting in the degradation of SOCS3. Therefore, SOCS2 can enhance cytokine responses by accelerating proteasome-dependent turnover of SOCS3, suggesting a mechanism for the gigantism observed in SOCS2 transgenic mice.

Citing Articles

Identification and validation of five ferroptosis-related molecular signatures in keloids based on multiple transcriptome data analysis.

Sun Z, Qin Y, Zhang X Front Mol Biosci. 2025; 11():1490745.

PMID: 39834787 PMC: 11743277. DOI: 10.3389/fmolb.2024.1490745.

Zileuton, a 5-Lypoxigenase Inhibitor, is Antiparasitic and Prevents Inflammation in the Chronic Stage of Heart Chagas Disease.

Ricci M, Lourenco E, Pereira R, Araujo R, Oliveira F, Barbosa da Silva E ACS Infect Dis. 2024; 10(12):4258-4270.

PMID: 39609255 PMC: 11650774. DOI: 10.1021/acsinfecdis.4c00623.

A loss of function mutation in SOCS2 results in increased inflammatory response of macrophages to TLR ligands and .

Guzylack-Piriou L, Gausseres B, Tasca C, Hassel C, Tabouret G, Foucras G Front Immunol. 2024; 15:1397330.

PMID: 39185412 PMC: 11341364. DOI: 10.3389/fimmu.2024.1397330.

Zfp36l1 establishes the high-affinity CD8 T-cell response by directly linking TCR affinity to cytokine sensing.

Petkau G, Mitchell T, Evans M, Matheson L, Salerno F, Turner M Eur J Immunol. 2023; 54(2):e2350700.

PMID: 38039407 PMC: 11146077. DOI: 10.1002/eji.202350700.

Structure-based design of a phosphotyrosine-masked covalent ligand targeting the E3 ligase SOCS2.

Ramachandran S, Makukhin N, Haubrich K, Nagala M, Forrester B, Lynch D Nat Commun. 2023; 14(1):6345.

PMID: 37816714 PMC: 10564737. DOI: 10.1038/s41467-023-41894-3.

References

Metcalf D, Greenhalgh C, Viney E, Willson T, Starr R, Nicola N . Gigantism in mice lacking suppressor of cytokine signalling-2. Nature. 2000; 405(6790):1069-73. DOI: 10.1038/35016611. View

Tanimoto K, Makino Y, Pereira T, Poellinger L . Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein. EMBO J. 2000; 19(16):4298-309. PMC: 302039. DOI: 10.1093/emboj/19.16.4298. View

Frantsve J, Schwaller J, Sternberg D, Kutok J, Gilliland D . Socs-1 inhibits TEL-JAK2-mediated transformation of hematopoietic cells through inhibition of JAK2 kinase activity and induction of proteasome-mediated degradation. Mol Cell Biol. 2001; 21(10):3547-57. PMC: 100276. DOI: 10.1128/MCB.21.10.3547-3557.2001. View

van de Geijn G, Gits J, Touw I . Distinct activities of suppressor of cytokine signaling (SOCS) proteins and involvement of the SOCS box in controlling G-CSF signaling. J Leukoc Biol. 2004; 76(1):237-44. DOI: 10.1189/jlb.0104041. View

Sasaki A, Yasukawa H, Suzuki A, Kamizono S, Syoda T, Kinjyo I . Cytokine-inducible SH2 protein-3 (CIS3/SOCS3) inhibits Janus tyrosine kinase by binding through the N-terminal kinase inhibitory region as well as SH2 domain. Genes Cells. 1999; 4(6):339-51. DOI: 10.1046/j.1365-2443.1999.00263.x. View

Kamura T, Sato S, Haque D, Liu L, Kaelin Jr W, Conaway R . The Elongin BC complex interacts with the conserved SOCS-box motif present in members of the SOCS, ras, WD-40 repeat, and ankyrin repeat families. Genes Dev. 1998; 12(24):3872-81. PMC: 317264. DOI: 10.1101/gad.12.24.3872. View

Kamizono S, Hanada T, Yasukawa H, Minoguchi S, Kato R, Minoguchi M . The SOCS box of SOCS-1 accelerates ubiquitin-dependent proteolysis of TEL-JAK2. J Biol Chem. 2001; 276(16):12530-8. DOI: 10.1074/jbc.M010074200. View

Hilton D, Richardson R, Alexander W, Viney E, Willson T, Sprigg N . Twenty proteins containing a C-terminal SOCS box form five structural classes. Proc Natl Acad Sci U S A. 1998; 95(1):114-9. PMC: 18144. DOI: 10.1073/pnas.95.1.114. View

Haan S, Ferguson P, Sommer U, Hiremath M, McVicar D, Heinrich P . Tyrosine phosphorylation disrupts elongin interaction and accelerates SOCS3 degradation. J Biol Chem. 2003; 278(34):31972-9. DOI: 10.1074/jbc.M303170200. View

10.

De Sepulveda P, Ilangumaran S, Rottapel R . Suppressor of cytokine signaling-1 inhibits VAV function through protein degradation. J Biol Chem. 2000; 275(19):14005-8. DOI: 10.1074/jbc.c000106200. View

11.

Greenhalgh C, Rico-Bautista E, Lorentzon M, Thaus A, Morgan P, Willson T . SOCS2 negatively regulates growth hormone action in vitro and in vivo. J Clin Invest. 2005; 115(2):397-406. PMC: 546423. DOI: 10.1172/JCI22710. View

12.

Hoeflich A, Wu M, Mohan S, Foll J, Wanke R, Froehlich T . Overexpression of insulin-like growth factor-binding protein-2 in transgenic mice reduces postnatal body weight gain. Endocrinology. 1999; 140(12):5488-96. DOI: 10.1210/endo.140.12.7169. View

13.

Iwai K, Yamanaka K, Kamura T, Minato N, Conaway R, Conaway J . Identification of the von Hippel-lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex. Proc Natl Acad Sci U S A. 1999; 96(22):12436-41. PMC: 22941. DOI: 10.1073/pnas.96.22.12436. View

14.

Ihle J . Cytokine receptor signalling. Nature. 1995; 377(6550):591-4. DOI: 10.1038/377591a0. View

15.

Starr R, Willson T, Viney E, Murray L, Rayner J, Jenkins B . A family of cytokine-inducible inhibitors of signalling. Nature. 1997; 387(6636):917-21. DOI: 10.1038/43206. View

16.

Naka T, Narazaki M, Hirata M, Matsumoto T, Minamoto S, Aono A . Structure and function of a new STAT-induced STAT inhibitor. Nature. 1997; 387(6636):924-9. DOI: 10.1038/43219. View

17.

Pezet A, Favre H, Kelly P, Edery M . Inhibition and restoration of prolactin signal transduction by suppressors of cytokine signaling. J Biol Chem. 1999; 274(35):24497-502. DOI: 10.1074/jbc.274.35.24497. View

18.

Cohney S, Sanden D, Cacalano N, Yoshimura A, Mui A, Migone T . SOCS-3 is tyrosine phosphorylated in response to interleukin-2 and suppresses STAT5 phosphorylation and lymphocyte proliferation. Mol Cell Biol. 1999; 19(7):4980-8. PMC: 84319. DOI: 10.1128/MCB.19.7.4980. View

19.

Hanada T, Yoshida T, Kinjyo I, Minoguchi S, Yasukawa H, Kato S . A mutant form of JAB/SOCS1 augments the cytokine-induced JAK/STAT pathway by accelerating degradation of wild-type JAB/CIS family proteins through the SOCS-box. J Biol Chem. 2001; 276(44):40746-54. DOI: 10.1074/jbc.M106139200. View

20.

Seki Y, Inoue H, Nagata N, Hayashi K, Fukuyama S, Matsumoto K . SOCS-3 regulates onset and maintenance of T(H)2-mediated allergic responses. Nat Med. 2003; 9(8):1047-54. DOI: 10.1038/nm896. View